Introduction: The development of proteasome inhibitor (PI) and immunomodulatory drugs
(IMiDs) and advances in supportive care have considerably changed the treatment …

Introduction: Multiple myeloma (MM) affected 14,400 new patients in the United States in
2002, and 50,000 total patients were affected. It remains incurable despite conventional and …

Recent leaps in elucidating the biology of myeloma, particularly the intracellular pathways
and the complex interaction with the bone marrow microenvironment, have resulted in an …

Introduction: Survival in multiple myeloma (MM) has improved significantly in the past 10
years due to new treatments, such as thalidomide and lenalidomide (immunomodulatory …

Multiple myeloma (MM) continues to evade cure by conventional therapies, increasing the
urgency for new, biologically based treatments. Reviewed in this discussion are novel …

Despite the advances in conventional, novel agent and high dose chemotherapy multiple
myeloma (MM) remains incurable. In order to overcome resistance to current therapies and …

In vitro and in vivo models have been developed that have allowed for delineation of
mechanisms of multiple myeloma (MM) cell homing to bone marrow (BM); tumor cell …

Recently, several advances have been made in understanding the pathogenesis of multiple
myeloma. Increasing evidence favours a pre-switched, but somatically mutated B-cell as …

Multiple myeloma (MM) remains incurable with conventional treatment approaches, and
novel biologically based therapies are therefore urgently needed. Targeted therapies are …

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000
new cases diagnosed each year. This exciting new text, edited by lauded authorities on the …